The Extra General Meeting in Initiator Pharma A/S (“Initiator Pharma” or “the Company”) decided, on the 11th of May 2021, to approve the Board of Directors proposal to execute a directed share issue of approx. SEK 30 million. Registration of the directed share issue at the Danish Companies Registration Office has now taken place and the total number of shares amounts to 35,813,834 and the share capital to DKK 3,760,452.57.
Upcoming preferential rights issue
As previously communicated, the Company intends to carry out a fully secured preferential rights issue of a total of approximately SEK 29.4 million. The subscription period for the forthcoming preferential rights issue has not yet been determined, as it is dependent on the Danish Financial Supervisory Authority's approval of the Company's prospectus. The prospectus is currently being reviewed by Finanstilsynet and as soon as the Company has further information on when an approval can be obtained, this will be announced to the market through a press release.
For further information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Phone: +45 6126 0035
The information was provided by the contact person above, to be published on the 20 of May 2021, at 16:30.
About Initiator Pharma
Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of three clinical programs - the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition. Initiator Pharma is listed on Spotlight Stockmarket (ticker: INIT).